MT 3724

Drug Profile

MT 3724

Alternative Names: MT3724

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator Molecular Templates
  • Developer Banner MD Anderson Cancer Center; Molecular Templates
  • Class Antibodies; Antineoplastics; Bacterial toxins; Immunoconjugates
  • Mechanism of Action CD20 antigen inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma

Most Recent Events

  • 01 Apr 2017 Preclinical data presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 30 Mar 2017 Pharmacodynamics data from a preclinical trial presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 30 Mar 2017 Molecular Templates plans a phase II trial in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top